Graybug Vision was founded in September 2011 as a spin-out of the world-renowned Wilmer Eye Institute of the Johns Hopkins University School of Medicine.

Graybug Vision is developing products to reduce the frequency of dosing for ocular therapies using its injectable controlled release technologies.  Our lead product, GB-102, has been demonstrated to provide a therapeutic levels of sunitinib (a VEGFR/PDGFR dual inhibitor) in preclinical studies reducing the potential frequency of dosing in neovascular age-related macular degeneration (nAMD) from every 4-8 weeks to as few as twice per year.  With this dual inhibition and reduced dosing frequency, GB-102, has the potential to become a best in class therapy for the treatment of nAMD. Graybug Vision’s technologies have solved the problems with tolerability and blockage of vision noted with many injectable sustained release ocular products. Our world-class team and advisors are experts in the development of controlled-release products and the treatment of ocular disease.

Graybug Vision’s technologies were initially co-developed by founder, Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute, Peter A. Campochiaro, MD and Peter J. McDonnell, MD These technologies were licensed from the Johns Hopkins University.  Graybug Vision has also established its own proprietary technologies to facilitate microparticle aggregation upon injection and developed a library of proprietary glaucoma and neuroprotection compounds for use as a twice a year subconjunctival injection in glaucoma therapy.